CPC A61K 31/337 (2013.01) [A61K 31/138 (2013.01); A61K 31/565 (2013.01); A61K 31/704 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] | 11 Claims |
1. A method of treating estrogen-responsive breast cancer (BC) in a human patient, which method comprises subjecting said patient to reduced caloric intake for a period of 24-190 hours while said patient is being treated with a compound having antiestrogenic activity, wherein said compound is a SERM and is selected among the group consisting of tamoxifen, raloxifene, toremifene, lasofoxifene, ospemifene, arzoxifene and bazedoxifene.
|